Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial

Yoshiaki Nakamura, Wataru Okamoto, Takeshi Kato, +24

Nature Medicine

Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients

Nozomu Fuse, Yasutoshi Kuboki, Takeshi Kuwata, +14

Gastric Cancer

Prognostic ImpactEsophageal CancerOverall SurvivalGastrointestinal OncologyMedicine +7

Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer

Tetsuhito Muranaka, Masaki Kuwatani, Yoshito Komatsu, +10

Journal of Gastrointestinal Oncology

Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer

Hideaki Bando, Yoshiaki Nakamura, Hiroya Taniguchi, +23

JCO Precision Oncology

Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)

Akihito Kawazoe, Yasutoshi Kuboki, Eiji Shinozaki, +13

Clinical Cancer Research

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

Yasuhide Yamada, Tadamichi Denda, Makio Gamoh, +17

Annals of Oncology

Randomized Controlled Trial on the Skin Toxicity of Panitumumab in Japanese Patients with Metastatic Colorectal Cancer: HGCSG1001 Study; J-STEPP

Yoshimitsu Kobayashi, Yoshito Komatsu, Satoshi Yuki, +20

Future Oncology

Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer

Kentaro Sawada, Yoshiaki Nakamura, Takeharu Yamanaka, +8

Clinical Colorectal Cancer

Prognostic BiomarkersMedicineHer2 AmplificationPathologyColorectal Cancer +5

Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer.

Satoshi Yuki, Hideaki Bando, Yuichiro Tsukada, +16

Journal of Clinical Oncology

Surgical OncologyRadiation TherapyPcr RateMedicineGastrointestinal Oncology +12

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study

Eiji Shinozaki, Takayuki Yoshino, Kentaro Yamazaki, +22

British Journal of Cancer